Rein Therapeutics Inc.
RNTX
$1.64
-$0.16-8.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.88% | 22.07% | 100.76% | 89.47% | 38.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.84% | 83.16% | 132.31% | 47.93% | -20.03% |
| Operating Income | -42.84% | -83.16% | -132.31% | -47.93% | 20.03% |
| Income Before Tax | -247.70% | -309.53% | -125.97% | -44.28% | 23.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -239.15% | -299.71% | -125.97% | -44.28% | 23.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -239.15% | -299.71% | -125.97% | -44.28% | 23.73% |
| EBIT | -42.84% | -83.16% | -132.31% | -47.93% | 20.03% |
| EBITDA | -43.78% | -84.18% | -133.42% | -48.40% | 20.03% |
| EPS Basic | 10.41% | -2.30% | -9.30% | 15.65% | 38.82% |
| Normalized Basic EPS | 61.89% | 42.52% | -18.04% | 10.80% | 35.60% |
| EPS Diluted | 10.41% | -2.30% | -9.30% | 15.65% | 38.82% |
| Normalized Diluted EPS | 61.89% | 42.52% | -18.04% | 10.80% | 35.60% |
| Average Basic Shares Outstanding | 284.51% | 289.11% | 200.83% | 106.58% | 21.96% |
| Average Diluted Shares Outstanding | 284.51% | 289.11% | 200.83% | 106.58% | 21.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |